First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Ambition for OzempicⓇ to become leading weekly GLP-1, with daily GLP-1 use shifting to oral semaglutide Promotional focus to shift from VictozaⓇ towards OzempicⓇ as market access emerges Aim for OzempicⓇ and oral semaglutide to replace VictozaⓇ as market leaders Commercial focus changing diabetes VICTOZA liraglutide injection Illustrative OZEMPİC semaglutide injection OzempicⓇ market access Prescription volume VICTOZAⓇ liraglutide injection OZEMPİC semaglutide injection Time 1 Victoza patent expiry expected in 2022/2023 in most markets Slide 65 Illustrative oral semaglutide VictozaⓇ patent expiry¹ novo nordisk

View entire presentation